MERCATOR

COMPANY PRESENTATION



Mercator Medical: Highly experienced and competent Management Board

MERCATOR

Dr Wiesław Żyznowski Founder & Chairman of the Board



- Founded Mercator Medical in 1996
- Since 2010 Chairman of the Management Board
- The Company's main shareholder
- A graduate of the Faculty of Management at the Cracow Economic Academy (currently Cracow University of Economics) and the Faculty of Philosophy at the Jagiellonian University in Cracow, where he received his PhD in philosophy

Witold Kruszewski Member of the Management Board



- Associated with Mercator Medical from 2013.
- From 11.2015 Member of the Management Board CFO.
- Before joining Mercator Medical, he worked, among others, in PHZ Baltona S.A. as a Member of the Management Board responsible for financials and in Mix Electronics S.A., as a Member of the Management Board responsible for financials.
- He is a certified auditor

Monika Żyznowska Member of the Management Board



- Associated with Mercator Medical since 2010.
- From 08.2017. Member of the Management Board and CEO of Mercator Medical (Thailand).
- Previously (2013-2016) she held formal positions in the Management Boards of Mercator Medical (Thailand) Ltd and its subsidiary Brestia Sp. z o.o. In the years 2010-2013 she worked for the international sales and finance departments of the Company.

Dariusz Krezymon Member of the Management Board



- Associated with Mercator Medical since 2016.
- Since 11.2019. Member of the Management Board of the Company.
- Before joining Mercator Medical he worked, among others, as the General Director in Organika RUS (Russia), as the Director of Trefl SA Factory and as Plant Director in IP Decora East (Belarus).

Mercator Medical: European leader in the medical gloves market





- Mercator Medical is a leading manufacturer and distributor of high quality disposable medical and protective gloves in Poland, with the status of one of the leaders on the European market, founded in 1996.
- The unique business model is based on:
 - production of disposable gloves in its own production facilities,
 - distribution of a wide range of medical and protective gloves, bandages and nonwoven products both for the medical market (hospitals, other medical entities, medical wholesalers) and the open market (retail chains and end customers).
- Strong competitive advantage in the form of company- owned own glove factories located in Thailand with a total production capacity of over 3 billion gloves per year. The company-owned factories secure the supply of gloves in the event of supply shortages from other manufacturers, while the location of the plants in Thailand allows to maintain relatively low levels of costs related to access to raw material and labour costs.
- The global nature of the business, supported by an extensive distribution network built up over the years - the Company is present in over 70 countries around the world.
- Participation in mWIG40 and international index MSCI Poland Small Cap. Opportunity to join WIG20 in the annual revision (March 2021)



1 of 2

entities in Europe and one of the few conglomerates in the world producing and distributing gloves in Asia globally

> >1 200 workers

glove factories located in Thailand

>3 billion units annual glove production

countries






PRESENTATION PLAN

- **1. MARKET OVERVIEW**
- 2. BUSINESS DESCRIPTION
- **3. FINANCIAL RESULTS**
- 4. STRATEGY AND PERSPECTIVES
- **5. APPENDICES**



MARKET OVERVIEW



Source: Malaysian Rubber Glove Manufacturers Association (MARGMA), Top Glove Investor Presentation 23.10.2020

Increasing role of healthcare around the world as a driver for further market growth

USDbn 18,9 (CAGR 13,5%) 6,9 2019 2027E


Over 2,5x forecasted market size growth until 2027*

Source: Allied Market Research - Disposable Gloves Market [...]: Global Opportunity Analysis and Industry Forecast, 2020–2027 *Forecast includes an influence of the COVID-19 pandemic on a disposable gloves market.

Global market growth drivers

- Increasing number of doctors
- Growing number of chronic diseases and increasing number of patients
- Increasing hygienic awareness
- Constant increase in hygiene standards of medical facilities
- Increase in the number of medical procedures requiring the use of gloves
- Growing percentage of people in emerging countries using both public and private medical facilities
- Increase in healthcare expenditures
- Aging of societies

Demand for gloves per captia (pcs, 2018) vs. **healthcare expenditures per capita** (USD ths, 2017)



Source: Hartalega Holdings Berhad - 12th Annual General Meeting (2018), WHO, Top Glove Investor Presentation 23.10.2020

D

The most attractive market growth prospects seem to rise in **developing countries**, whose healthcare sectors have been insufficiently equipped so far (incl. **China** and **Indie**).




Additional demand for medical gloves related to **COVID-19 vaccines** may amount to **10-14 billion gloves in 2021-22**.



Crucial surplus of demand over supply as a factor of increasing market prices




Limited production growth as driver of increase in prices *Production of the 5 largest gloves manufacturers (billion pcs)*



Source: Companies' data, KS Research

ASP* growth on the example of Sri Trang Gloves USD** per thousand gloves



In case of Mercator, in this period, a higher increase in prices was experienced, resulting from faster price increases, lower exposure to fixed price contracts and lower share of natural latex gloves.

Source: Sri Trang Gloves - 3Q20 Analyst Presentation | *Average Selling Price | **Calculation of THB prices based on average quaterly USD/THB exchange rates.

 $\mathbf{\Sigma}$

Due to the specificity of the industry, the potential periodic increase in the production capacity of companies producing rubber gloves is relatively small due to the **limited supply possibilities of raw materials and the time needed to build the capacity**.

 $\mathbf{\Sigma}$

Faced with the inflow of huge demand in the context of the COVID-19 pandemic, glove market has experienced significant surplus of demand, which resulted in higher prices and a significant extension of the waiting period for disposable gloves.

In the case of Top Glove, which is the largest manufacturer of gloves in the world, the waiting period for gloves has been extended to nearly two years (approx. 660 days).

Further dynamic market development – the largest glove producer's forecasts



TOP QUALITY, TOP EFFICIENCY

No. 1 global glove producer

- Currently, the time for the delivery of gloves is around 660 days, while before the pandemic this period was usually 30-40 days.
- It will take up to two years for potential competitors to enter the market due to supply constraints and scale of operations.
- Following the end of the COVID-19 pandemic, glove use is expected to increase compared to the pre-pandemic period due to an increase in the health sector and hygiene awareness.
- Growth in global glove demand in the coming years will exceed the expected additional supply from major glove producers in Malaysia, Thailand and China.
- Further projected increase in the average selling price (ASP) of gloves due to increased demand, rising raw material costs and increase in operating costs -ASP is expected to increase by 30% QoQ in Q4.
- Nitrile latex prices are expected to increase due to raw material supply constraints.

Key concers and mitigants related to market outlook





Maintaining sales volumes after the pandemic





Decline in market prices for gloves



Temporary factory closures as a result of a COVID-19 outbreak among workers



New competitors entering the market



- The growing role of the healthcare sector around the world
- Potential demand from underfunded and ill-equipped health sectors in emerging countries (including China and India)
- Increased hygiene awareness and sanitary requirements
- The forecasted price of gloves after the end of the COVID-19 pandemic at a level **clearly** above the market prices before the pandemic (approx. + 50%)
- The process of vaccinating the entire population over time will guarantee **increased demand also in the coming years**
- Additional demand for medical gloves related to COVID-19 vaccines will be 10-14 billion gloves in 2021-22.
- The invention of the vaccine and the commencement of the vaccination process of societies should contribute to reducing the incidence of COVID-19 and thus reducing the risk of the need to periodically close factories
- Closure of factories by competitors may deepen the advantage of demand over supply and prolong the trend of positive changes in market conditions from the point of view of producers
- Numerous entry barriers for new players on the market
- Long preparation time required to start a production
- Limited supply of raw materials
- The expected demand exceeds the potential supply from the major producers



BUSINESS DESCRIPTION

Unique business model: Effective vertical integration providing extensive market knowhow



Mercator Medical has been operating on the market of disposable medical and protective products for over 20 years. The Company's business model is based on 2 main operating segments: **1** Production of disposable medical gloves, and 2 Distribution of disposable medical and protective materials. 2 **Distribution** Production Within the production segment, the Company produces Within the distribution segment, the Company sells to disposable gloves and then sells them in container units the medical and open markets medical goods **Description of segments** to customers around the world. purchased from recognized external suppliers (including Mercator Medical Thailand). Synthetic latex disposable medical gloves - the fastest Medical and protective gloves, dressing materials, **Products** growing glove segment on the market surgical field covers **Production capacity /** Over 3 bn gloves are produced annually in 2 production ca. 3 bn gloves per year* volumes plants Share in revenues 52% (vs. 45% in 1-3Q 2019) 48% (vs. 55% in 1-3Q 2019) 1-3Q 2020


*estimated data at the end of 2020

Vertical integration of the business allows the Company to implement the strategy of maximizing its share in the global market by offering a broad product portfolio consisting of ca. 120 own and recognized international manufacturers products, meeting the expectations of customers

Own production plants in Thailand ensuring flexibility and providing the potential to respond to global changes in demand



Factories located near a developed port infrastructure



Key advantages of own production plants

- **Production flexibility** ensuring the ability to adapt the offer to global trends
- Secured supplies of gloves in case of supply shortages from other manufacturers

Production of disposable nitrile gloves - the fastest growing segment of the disposable gloves market

Geographic rent, thanks to the convenient location of the plants near the developed port infrastructure

- Mercator Medical has 2 production plants in Thailand (17 production lines in total), manufacturing disposable medical gloves made of industrially sourced synthetic latex with a total production capacity of about 270 million gloves per month (over 3 bn gloves per year).
- The plants are located in a convenient location, close to the well-developed port infrastructure in the Songkhla (Thailand) and Penang (Malaysia).
- The factory employs **more than 1 000 workers**, about 50% of whom work at the production lines.
- Products manufactured at the Thai production facilities are sold to ca. 70 countries around the world, most of which are exported to the United States, Australia and the United Kingdom.


Mercator Medical factory in Thailand



*estimated data at the end of 2020

Distribution activity ensuring an extensive and diversified product portfolio covering both medical and non-medical areas

Mercator Medical revenues by geographical breakdown



- Within the distribution segment, Mercator sells ca. 3 bn gloves annually*.
- Products manufactured in the Company's own production plants account for ca. 6%* of the volumes sold within the distribution segment.
- Within the distribution segment, Mercator purchases a wide range of medical and protective products from recognizable and international producers.
- The Company conducts direct distribution through commercial companies in Russia, Romania, Ukraine, Hungary, the Czech Republic, Italy and Germany, where it employs a total of ca. 150 employees (mainly factory managers, sales and warehouse employees).
- An efficient model with a distribution part allows the Company to offer an extensive portfolio of gloves for various applications, not only in the medical area.

MERCATOR



FINANCIAL RESULTS

Dynamic revenue growth in both business segments

540 420 +144%301 264 227 168 148 2013 2015 2016 LTM 2014 2017 2018 2019


Nearly 2.5-fold increase of LTM revenues vs. FY 2019

Products: Rising prices are driving revenue growth*

Total revenue in annual terms (PLN million)

Over 60% q/q revenue growth in Q3 2020


Decomposition of revenue in guarterly terms (PLN million)



Diagnostic gloves

Product sales on a quarterly basis (PLN million) 348 +7 +150 +31 190 +82 78 +14 66 -2 Q4 '19 Q1 '20 Q2 '20 Q3 '20 Price Volume Price Volume Price Volume Source: the Company | *The analysis includes only diagnostic gloves, which constitute 97.7% of total sales revenue in Q3 2020

Goods: Volume decrease neutralized by price increases* Sales of goods and materials on a quarterly basis (PLN million)




1320


MERCATOR

Increase in profitability in recent quarters


MERCATOR



Simultaneous increase of profits from production and distribution Decomposition of EBITDA* for production and distribution (PLN million)




Significant increase in profitability in both segments *EBITDA profitability* by segments on a quarterly basis (%)*



- In recent quarters the Company has experienced a simultaneous increase in profitability in both business segments.
- In the case of manufacturing operations, the margin increased to 75%, while in the distribution segment, profitability was about 54%.
- According to the Management Board's estimates, the target profitability (taking into account developments under the new strategy) in the period after the COVID-19 pandemic (i.e. after 2022) in the production segment is expected to be about 25%, while profitability in the production segment may be about 15%.

Strong cash position will allow for further development and payment of high dividends



154

Q2 '20

Q3 '20

×139

15

Q1 '20

High level of EBITDA to cash conversion (PLN million)

79%

235

185

Q2 '20

DIVIDEND PLANS

35

Q1 '20

EBITDA

8

Q4 '20

CFO

In June 2020, the Company paid 0.50 PLN in dividends per share for 2019 - a total 5.3 million PLN.

Q3 '20

Because of good financial results in 2020, Mercator initiated a **share buy-back program**, under which it plans to allocate **PLN 30.7 million** for share purchase and redemption.

15

Q4 '19

In 2021 and 2022, the Company plans to allocate approximately 35% of the Company's consolidated net profit generated in 2020 and 2021 respectively to the dividend and/or share buy-back program.

Source: The Company |*In relation to the total number of the Company's shares before the buy-back and redemption of shares under the share buy-back program.



PERSPECTIVES

Mercator Medical: Attractive exposure to a globally unique business model and structural growth of the sector



2

3

4

5

A wide portfolio of products consisting of approx. 120 proprietary products and goods from recognizable and global producers

on a unique strategy in the branch in the field of both production and distribution of medical disposables.

Market leader on the disposable gloves market in Europe and with a strong position on the global market, based

Own production facilities in Thailand, ensuring flexibility and the ability to respond to global trends and changes in demand

An extensive distribution network based on many years of activity in the industry, ensuring global sales of products in over 70 countries

Significant increase in cash on the balance sheet and potential significant financial flows in the coming quarters ensuring further acceleration of the Company's growth

Significant weighting in the WIG index, participation in the MSCI Poland Small Cap index and the possibility of moving to the WIG20 index

Business activity on a prospective market supported by i.a., the global trend of increasing health care spending, growing public awareness of hygiene and increasingly higher hygiene standards


7



APPENDICES

Possible increase in costs triggered by rising nitrile latex prices





Comparison of operating costs (PLN million)

Potential significant excess of demand over NBR supply

- The biggest factor in the Company's operating costs is the potential change in the price of nitrile latex (NBR) in the South East Asia region. In recent months, an upward trend in the price of the latex can be observed.
- Apart from the prices of nitrile latex, the most important components of the Company's operating costs are expenses related to other chemical substances, energy demand and salaries for the Company's employees.
- It is worth noting that both on the income and cost side the Company is clearly dependent on the changing exchange rates (among negative exposure to USD).

Mercator Medical's entry into the international MSCI Small Cap index and the possibility to move to the WIG20 index



Potential entry of the Company into the WIG20 index as part of the annual revision



- In June 2020, Mercator Medical entered the mWIG40 index as part of the quarterly revision of index portfolios.
- The increase in the Company's market capitalization and the continuing high level of trading of Mercator Medical shares constitute a strong premise for the Company's entry into the WIG20 index in March 2021 as part of the annual revision.
- Taking into account the methodology of calculating ranking points, considering e.g. shares trading for the last 12M and their growth in recent months, each subsequent month should work in favor of the Company.

Mercator Medical in the prestigious MSCI Small Cap index



 Strong financial results and recognition among investors ensured the Company's entry into the international MSCI index for small companies as part of the half-yearly review conducted on 10 November 2020.

Disclaimer



This presentation ("Presentation") was prepared by Mercator Medical S.A. (the "Company") and IPOPEMA Securities S.A. ("IPOPEMA") for information purposes only. The presentation does not constitute an offer to sell or solicitation of an offer to buy or sell any financial instrument, cannot be relied upon in connection with any contract or commitment and does not constitute an advertisement or promotion of a financial instrument or the Company.

IPOPEMA Securities S.A. with registered office in Warsaw, is a licensed brokerage house operating on the basis of the license issued by the Polish Securities and Exchange Commission (presently the Polish Financial Supervision Authority – Komisja Nadzoru Finansowego) dated 30 June 2005. IPOPEMA Securities S.A. is entered in the National Court Register maintained by the District Court for the Capital City of Warsaw, 12th Commercial Division of the National Court Register, under number KRS 0000230737, NIP (tax identification number): 527-24-68-122, share capital: PLN 2.993.783,60 paid up in full. IPOPEMA Securities S.A is supervised by the Polish Financial Supervision Authority (Komisja Nadzoru Finansowego), ul. Piękna 20, 00-549 Warsaw, Poland.

This Presentation presents information about Mercator Medical S.A. but at the same time the information presented in this Presentation does not constitute: (i) a memorandum or prospectus within the meaning of the Act of 29 July 2005 on Public Offering, Conditions Governing the Introduction of Financial Instruments to Organized Trading and Public Companies and the Regulation of the European Parliament and the Council (EU) 2017/1129; (ii) an offer within the meaning of the Act of 23 April 1964. - Civil Code; (iii) a share purchase proposal; or (iv) an invitation to purchase shares. This Presentation does not constitute a 'recommendation' or 'information recommending or suggesting an investment strategy' within the meaning of Art. 3 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) on market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC, relating to the company or securities issued by it and does not constitute an 'investment advice' or 'investment advice' or 'investment advice' within the meaning of the Act of 29 July 2005 on trading in financial instruments. This Presentation does not constitute an 'investment research' or 'marketing communications' within the meaning of Commission Delegated Regulation (EU) 2016/958 of 25 April 2016 supplementing Directive 2014/65/EU of the European Parliament and of the Council as regards organizational requirements and operating conditions for investment firms and defined terms for the purposes of that Directive. It is recommended that each person intending to make any investment decision regarding the securities issued by the Company, should rely on the information contained in the current reports of EIB/ESPI and periodic reports made public.

The information contained in the Presentation is not profiled in relation to particular recipients, i.e., it is not based on the needs and situation of a particular recipient, including knowledge, experience, investment objectives and appetite for recipient risk. Investment products are subject to investment risk, including the possibility of losing some of the invested funds. Investment results achieved in the past are of historical nature and cannot constitute a guarantee of achieving investment goals or obtaining similar results in the future. This Presentation cannot be regarded as equivalent to investment advice. The value of financial instruments may fluctuate, including the possibility of a decrease. Changes in exchange rates may have a negative impact on the value of investments. The price of financial instruments is affected by many different factors, which are or may be independent of the issuer and its performance. These may include, among others, changing economic, legal, political and tax conditions.

Recipients should assume that IPOPEMA Securities S.A. or related entities can provide services to Mercator Medical S.A. and receive remuneration for this. They may also have other relations with the Company. IPOPEMA Securities S.A. or its affiliates may establish business relations with the Company or other entities listed in the document. IPOPEMA has an organizational structure and internal regulations ensuring that the investor's interests will not be affected in the event of a conflict of interest, in connection with the preparation of this Presentation. IPOPEMA's conflicts of interest management policy is available on its website at https://www.ipopemasecurities.pl.

The presentation contains basic information, statements and estimates. Neither the Company nor IPOPEMA can guarantee the accuracy and completeness of the information contained in this Presentation. Neither the Company nor IPOPEMA, nor the members of its bodies, employees, advisors, their representatives or other persons involved in preparing this Presentation make any representations or warranties, express or implied, as to the reliability, accuracy, completeness or correctness of the information and opinions contained in this Presentation, nor do they accept any liability for any reason related to its use. Furthermore, no information contained in this Presentation constitutes a commitment or representation by the Company, IPOPEMA or designated persons. This Presentation contains forward-looking information, but such information cannot be relied upon as assurances or forecasts of expected future events and results. Actual events and results may differ materially from the expected future events and results described in this Presentation. Under no circumstances should the content of this Presentation be construed as any express or implied statement or assurance made by the Company, IPOPEMA or their representatives. The information contained in this Presentation has not been independently verified and may change at any time without prior notice. Neither the Company nor IPOPEMA is obliged to update this Presentation.

This Presentation may not be made available, copied or quoted without prior written consent of IPOPEMA Securities S.A. In particular, neither this Presentation nor any copy of it may be distributed directly or indirectly in the United States of America, Australia, Japan or Canada, or transmitted to citizens or residents of a country where its distribution may be restricted by applicable law. Recipients who come into possession of the Presentation should be informed of and comply with any related restrictions. Failure to comply with such restrictions may constitute a violation of the securities laws of that jurisdiction.

MERCATOR

CONTACT FOR INVESTORS:

Bogna Sikorska b.sikorska@pandl.pl +48 501 239 339 Adrian Boczkowski a.boczkowski@pandl.pl +48 506 324 456